Wedoany.com Report-Dec.8, Thermo Fisher Scientific has expanded its bioprocessing footprint across Asia with the opening of a new Bioprocess Design Center in Hyderabad, India, and upgrades to existing centers in Incheon, Korea and Singapore. The investments create a connected regional network aimed at accelerating development and manufacturing of biologics, vaccines, and cell and gene therapies.

The three centres now form an integrated tri-hub system that brings advanced laboratory capabilities, process simulation tools and technical expertise closer to customers throughout Asia.

- Incheon, Korea: The expanded facility offers enhanced laboratory space and access to latest-generation materials and technologies for collaborative process development.

- Hyderabad, India (Genome Valley): The newly established centre, developed in cooperation with the Government of Telangana, provides dedicated spaces for process design, testing and optimisation using modern single-use and hybrid bioprocessing systems.

- Singapore: The upgraded site supports bench-to-pilot scale activities, expert training programmes and close technical collaboration to scale early-stage processes efficiently.

Daniella Cramp, Senior Vice President and President, BioProduction at Thermo Fisher Scientific, said:"Asia continues to play an increasingly important role in advancing innovation across the global biopharma industry. By expanding our network in Korea, Singapore and India, we're bringing world-class infrastructure and expertise closer to our customers, helping them deliver high-quality biologics faster, more cost-effectively and more sustainably."

Tony Acciarito, President, Asia Pacific and Middle East, Africa at Thermo Fisher Scientific, added: "Through advanced manufacturing, strategic partnerships and targeted regional investments, we are redefining what is possible in biologics production. We are proud to contribute to the transformation of Asia’s biopharma ecosystem and help our customers bring life-changing therapies to patients across Asia and beyond."

The expanded network supports customers from early research through commercial production, offering localised access to Thermo Fisher's full portfolio of bioprocessing technologies, analytical instruments and pharma services. The initiative strengthens the company's ability to meet rising regional demand while promoting faster, more flexible and sustainable biomanufacturing practices.